Name | Mavodelpar |
---|
Description | Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1]. |
---|---|
Related Catalog | |
In Vivo | Mavodelpar (10 mg/kg;腹腔注射,10 mg/kg,每日 1 次,6-17 周龄) 可有效抑制肾小球损伤和肾纤维化,并降低纤维化相关蛋白的水平[1]。 Animal Model: Male and female B6129SF1-Col4a3-/- mice[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV. |
References |
Molecular Formula | C31H29FNNaO5 |
---|---|
Molecular Weight | 537.55 |